B. Kim Lee Sim has over 25 years of experience in vaccine development and research. Dr. Sim did her undergraduate (BS, Honors, First Class) and graduate studies (MS, PhD) at the University of Malaya, Kuala Lumpur, Malaysia. After a post doctoral fellowship in molecular biology at Harvard School of Public Health, she was a research scientist at the Walter Reed Army Institute of Research and an adjunct faculty at the Uniformed Services University of Health Sciences, a research assistant professor at Johns Hopkins School of Public Health, and an Expert at the National Institute of Allergy and Infectious Diseases, NIH. In 1993 Dr. Sim left the NIH to join a start up company, EntreMed Inc, as Research Director of Molecular Biology, and in 1999 she was appointed Vice President Pre-Clinical Research and Development. At EntreMed Dr. Sim established and managed the development program for anti-angiogenic proteins for the therapy of cancer, and developed the process that led to the cGMP manufacture of tens of kilograms of recombinant Angiostatin and Endostatin, two anti-angiogenic proteins that entered Phase II clinical trials. Dr. Sim is also the Executive Vice President of Process Development and Manufacturing at Sanaria Inc., a company developing a live attenuated whole organism malaria vaccine (www.sanaria.com). Dr. Sim is a Board Member of Sanaria Inc. Dr. Sim has published more than 85 scientific papers, and has 7 issued and more than 15 pending patents. 

 Protein Potential provides purified recombinant proteins and DNA plasmids for research and development, process development, documentation, and technological know-how to transition therapeutic, vaccine, diagnostic proteins and DNA plasmids to large scale cGMP (Good Manufacturing Practices) manufacture.